Our group has long-standing experience in cellular and molecular biology, especially focused on the stem cell and cardiovascular fields. We have provided mechanistic insights into the pathogenesis of cardiomyopathies and this basic knowledge has led to the development of novel advanced therapeutics (nanotechnological/bioengineering-based), validated both in our murine and pre-clinical pig models of cardiac disease. The development of the basic and pre-clinical research lines of the group have been possible thanks to the funding obtained by national, and international grants (MEraNet-2023, SUDOE-2020, Aquitania-Euskadi-Navarra-2019, EuroNanoMed-2015…), some of them coordinated by the group. We have also long-term experience in collaborative work with international companies, with a PCT international Patent Application and know-how transferring for the preparation of therapeutic cellularized patches in cardiovascular applications. This has allowed starting a Clinical Trial in patients with ischemic cardiomyopathy.
